John Gordan, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
John Gordan, MD, PhD

Adjunct Instructor, Division of Hematology/Oncology, UCSF

John.Gordan@ucsf.edu

Phone: (415) 353-9888
Box 3211, UCSF
San Francisco, CA 94143

UCSF Profiles

Cancer Center Membership

Member » Developmental Therapeutics

Education

Harvard College, Cambridge, MA, BA, 06/2001, Biochemistry
University of Pennsylvania School of Medicine, Philadelphia, PA, PhD, 12/2007, Cancer Biology
University of Pennsylvania School of Medicine, Philadelphia, PA, MD, 05/2009, Medicine
UC San Francisco, Resident, 06/2011, Internal Medicine
UC San Francisco, Clinical Fellow, 07/12, Hematology/Oncology


Professional Experience

  • 2009-2011
    Resident, Internal Medicine and Molecular Medicine Training Program, UCSF
  • 2011-2015
    Fellow, Division of Hematology/Oncology, UCSF, Research phase in the laboratory of Kevan Shokat
  • 2015 - present
    Adjunct Instructor, Division of Hematology/Oncology, UCSF

Honors & Awards

  • 2007
    Nachmias Thimann Prize for Outstanding Graduate Research in Cell and Developmental Biology, University of Pennsylvania
  • 2008
    AACR-GlaxoSmithKline Outstanding Clinical Scholars Award
  • 2008
    Saul Winegrad Award for Outstanding Dissertation in Cell and Molecular Biology, University of Pennsylvania
  • 2008
    AOA Medical Honor Society.
  • 2009
    Kanovsky Prize for the best medical student entering Internal Medicine, University of Pennsylvania.
  • 2015
    American Society for Clinical Oncology Young Investigator Award

Selected Publications

  1. Urisman A, Levin RS, Gordan JD, Webber JT, Hernandez H, Ishihama Y, Shokat KM, Burlingame AL. An optimized chromatographic strategy for multiplexing in parallel reaction monitoring mass spectrometry: Insights from quantitation of activated kinases. Mol Cell Proteomics. 2016 Dec 11.
    View on PubMed
  2. Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, Shokat KM, Bandyopadhyay S, Lord CJ, Ashworth A. Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib. Mol Cancer Ther. 2016 Jul; 15(7):1472-84.
    View on PubMed
  3. Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo JC, Shi L, Kato Y, Levin RS, Webber JT, Damon LJ, Egan RK, Greninger P, McDermott U, Garnett MJ, Jenkins RL, Rieger-Christ KM, Sullivan TB, Hezel AF, Liss AS, Mizukami Y, Goyal L, Ferrone CR, Zhu AX, Joung JK, Shokat KM, Benes CH, Bardeesy N. Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discov. 2016 Jul; 6(7):727-39.
    View on PubMed
  4. Evason KJ, Francisco MT, Juric V, Balakrishnan S, Lopez Pazmino Mdel P, Gordan JD, Kakar S, Spitsbergen J, Goga A, Stainier DY. Identification of Chemical Inhibitors of ß-Catenin-Driven Liver Tumorigenesis in Zebrafish. PLoS Genet. 2015 Jul; 11(7):e1005305.
    View on PubMed
  5. Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji AF, Schreiber SL, Krogan NJ, Shokat KM, McCormick F, Goga A, Bandyopadhyay S. Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Cancer Discov. 2015 Feb; 5(2):154-67.
    View on PubMed
  6. Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F, Bandyopadhyay S, Shokat KM. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep. 2014 Aug 21; 8(4):1037-48.
    View on PubMed
  7. Dondeti VR, Wubbenhorst B, Lal P, Gordan JD, D'Andrea K, Attiyeh EF, Simon MC, Nathanson KL. Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res. 2012 Jan 1; 72(1):112-21.
    View on PubMed
  8. Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP, Venook AP. "And what other medications are you taking?". J Clin Oncol. 2011 Apr 10; 29(11):e288-91.
    View on PubMed
  9. Bertout JA, Majmundar AJ, Gordan JD, Lam JC, Ditsworth D, Keith B, Brown EJ, Nathanson KL, Simon MC. HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci U S A. 2009 Aug 25; 106(34):14391-6.
    View on PubMed
  10. Wright TM, Brannon AR, Gordan JD, Mikels AJ, Mitchell C, Chen S, Espinosa I, van de Rijn M, Pruthi R, Wallen E, Edwards L, Nusse R, Rathmell WK. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene. 2009 Jul 9; 28(27):2513-23.
    View on PubMed
  11. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008 Dec 9; 14(6):435-46.
    View on PubMed
  12. Young RM, Wang SJ, Gordan JD, Ji X, Liebhaber SA, Simon MC. Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism. J Biol Chem. 2008 Jun 13; 283(24):16309-19.
    View on PubMed
  13. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell. 2007 Aug; 12(2):108-13.
    View on PubMed
  14. Lum JJ, Bui T, Gruber M, Gordan JD, DeBerardinis RJ, Covello KL, Simon MC, Thompson CB. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev. 2007 May 1; 21(9):1037-49.
    View on PubMed
  15. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell. 2007 Apr; 11(4):335-47.
    View on PubMed
  16. Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev. 2007 Feb; 17(1):71-7.
    View on PubMed
  17. Zhang F, Hamanaka RB, Bobrovnikova-Marjon E, Gordan JD, Dai MS, Lu H, Simon MC, Diehl JA. Ribosomal stress couples the unfolded protein response to p53-dependent cell cycle arrest. J Biol Chem. 2006 Oct 6; 281(40):30036-45.
    View on PubMed
  18. Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, Hu CJ, Labosky PA, Simon MC, Keith B. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 2006 Mar 1; 20(5):557-70.
    View on PubMed
  19. Wang H, McCann FE, Gordan JD, Wu X, Raab M, Malik TH, Davis DM, Rudd CE. ADAP-SLP-76 binding differentially regulates supramolecular activation cluster (SMAC) formation relative to T cell-APC conjugation. J Exp Med. 2004 Oct 18; 200(8):1063-74.
    View on PubMed
  20. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol. 2004 Oct; 24(19):8477-86.
    View on PubMed

Go to UCSF Profiles, powered by CTSI